This observational study, called GRAfT 2.0, aims to understand why some people develop rejection after a lung transplant and others do not. After a lung transplant, some people develop donor-specific antibodies (DSA), which are proteins that can cause the body to treat the new lungs as foreign. However, not everyone with DSA experiences rejection. Researchers want to find out the molecular differences between people with DSA who develop rejection and those who don't. You may be able to join if you are 18-75 years old and have progressive lung disease, or have had or are being evaluated for a lung transplant. The study is looking for 100 participants to help identify why rejection happens, with the goal of finding ways to prevent it.

Study design

This is an observational study with a planned enrollment of 100 participants. It is not testing a specific intervention or drug.

What's involved

You will have clinic visits every 3 to 6 months for up to 4 years. These visits will involve blood draws, bronchoscopy (a procedure to look at your airways), imaging, and other diagnostic tests.

Compensation

Not stated in the trial record.

Follow-up

The primary goal is to measure molecular differences at 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.